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Questions

What is already known about this topic?


Considerable effort has been devoted to developing an effective non-invasive method
of monitoring disease progression and outcome among cancer patients. One method is
multimarker qRT-PCR used to detect circulating tumour cells in patient blood. In
breast, colorectal and prostate cancer circulating tumour cells correlate with both
disease progression and poor treatment outcome. Circulating cell analysis in
melanoma has had varied success; despite the capacity to detect cells the appropriate
markers remain undefined.

What does this study add?


This is the first application of ABCB5 as a marker of circulating melanoma cells,
incorporated into a multi marker qRT-PCR test of melanoma patient blood. Expressed
by a subset of melanoma cells with a stem cell phenotype, its detection in this study,
along with MLANA a melanocyte marker, correlated with disease recurrence,
suggesting both stem and non-stem cell phenotypes are present in patient peripheral
blood. MCAM expression is shown for the first time to correlate with negative
treatment outcomes.
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ABSTRACT
Background: Multimarker quantitative real-time PCR (qRT-PCR) represents an effective
method for detecting circulating tumour cells in the peripheral blood of melanoma patients.
Objectives: The aim of this study was to investigate whether the phenotype of circulating
melanoma cells represents a useful indicator of disease stage, recurrence and treatment
efficacy.
Methods: Peripheral blood was collected from melanoma patients (n=230) and healthy
controls (n=152) over a period of three years and nine months. Clinical data and blood
samples were collected from patients with primary melanoma (early stages 0-II (n=154)) and
metastatic melanoma (late stages III-IV (n=76)). Each specimen was examined by qRT-PCR
analysis for the expression of five markers: MLANA, ABCB5, TGFβ2, PAX3d and MCAM.
Results: Two hundred and twelve melanoma patients (92%) expressed markers in their
peripheral blood. Two markers, MLANA and ABCB5, had the greatest prognostic value, and
were identified as statistically significant among patients who experienced disease recurrence
within our study period, being expressed in 45% (MLANA) and 49% (ABCB5) of patients
with recurrence (p=0.001 & p=0.031). For patients administered non-surgical treatments,
MCAM expression correlated with poor treatment outcome.
Conclusion:
Circulating tumour cells were detectable at all stages of disease and long after surgical
treatment even when patients were considered disease free. Specifically, expression of
ABCB5 and MLANA had significant prognostic value in inferring disease recurrence while
MCAM expression was associated with poor patient outcome after treatment, confirming
multimarker qRT-PCR as a potential technique for monitoring disease status.
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Introduction
Cutaneous melanoma is a tumour originating from normal skin melanocytes. Global
incidence of melanoma is increasing1, with an estimated 70,230 new cases annually in the
USA 2. Melanoma has a high metastatic potential 3 and metastatic melanoma is difficult to
treat . It is important therefore to find methods of detecting melanoma spread at early stages
for more accurate treatment and prediction of prognosis.
A staging system was devised by the American Joint Committee on Cancer (AJCC) based on
histological features of the primary lesion, and the presence of nodal and/or systemic
metastases in advanced disease 3. Due to increased awareness, most patients present with
thin, localised melanoma which is usually curable by surgical resection. However,
approximately 5% of patients with lesions <1 mm thick, 25-40% with 2 to 4 mm lesions and
50-75% with lesions > 4 mm develop metastatic disease and die within ten years 3. Patients
diagnosed with regional and distant metastases have 10 year survival rates of 64% and 16%
respectively 4.
Patients may suffer relapse following disease free periods of ten years or more 5,6. Evidently
then, diagnosing patients as clinically disease free after surgical removal of early stage
melanomas, may be inaccurate, since tumour cells dispersed into the bloodstream may
remain dormant, prior to formation of distant metastases 7.
Considerable research into the detection of circulating tumour cells in the blood of patients
with breast, colorectal and prostate cancer has shown that the presence of these cells
correlates with both disease progression and poor outcome8-16. For melanoma, circulating cell
analysis has not been successfully utilised clinically. Although several articles have indicated
their usefulness17-22, markers and methodology remain controversial. Moreover, it is unclear
4
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whether circulating melanoma stem cells are prognostic 23 or whether all circulating
melanoma cells have metastatic potential 24.
Here we used multimarker qRT-PCR to investigate the phenotype of circulating cells in
melanoma patients. Given qRT-PCR sensitivity, it is suitable for assessment of rare
circulating melanoma cells 25 and multiple markers are essential given the heterogeneous
nature of melanoma cells 18,26. Our markers included melanocyte (PAX3d 27 and MLANA 28),
tumour (TGFβ2 29 and MCAM 30) and stem cell (ABCB5 31) markers. PAX3 regulates
melanocytic development 32-34, and the PAX3d isoform is highly expressed in melanoma 35.
ABCB5 a stem cell marker, marks a subset of rare, chemoresistent melanoma stem cells
24,31,36

, while MCAM is a marker of melanoma tumour progression 34.

We show that circulating tumour cells are detectable at all stages of disease and persist long
after treatment. Certain circulating cells, specifically those marked by MCAM expression,
correlated with a poor treatment outcome, while ABCB5 and MLANA, correlated with
disease progression and could aid in monitoring disease status.
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Material and Methods
Patient cohort
Patient (230) and healthy control (152) participants provided written consent. Patients were
recruited from the Medical Oncology Department of Sir Charles Gairdner Hospital and the
Perth Melanoma Clinic at Hollywood Hospital (Perth, Western Australia) and consisted of 81
females and 149 males aged 24 – 96 (mean 69 years) while the aged matched, healthy cohort,
recruited from the general population, contained 86 females and 66 males aged 18-99 (mean
51 years). The Human Research Ethics Committees of Edith Cowan University (No. 2932)
and Sir Charles Gairdner Hospital (No. 2007-123) approved the study.
The study included 154 patients with primary cutaneous melanoma and 76 with metastatic
melanoma. AJCC Clinical staging categorised 16.5% of our patients as stage 0, 33.5% as
stage I, 17% as stage II, 13% as stage III and 20% as stage IV (Table 2). Patients were
sampled only once and clinical history recorded, however a subset of patients (n=140) were
sampled serially throughout the 3.9 year study. Tumour burden was calculated from
pathology reports for a subset of 32 patients, by calculating the sum of maximal tumour
diameters for all tumours within the patient, at the time of sampling.
Melanoma cell lines
Human melanoma cell line A2058 cells (EACC: 91100402), were grown in DMEM media
containing 10% heat inactivated foetal bovine serum (Invitrogen) in a T75-cm2 flask
(Greiner) until cells were ~70% confluent.
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Blood Collection, RNA Isolation and Amplification Protocols
At venipuncture, the first 4 mL of blood was discarded to avoid epithelial contamination 37.
2.5mL of whole blood was then collected into a PAXgene Blood RNA Tube (PreAnalytiX),
containing RNA stabilisers 38.
Total RNA was isolated using the PAXgene Blood RNA kit (Qiagen) and DNase treated
(DNA-free Kit, Ambion). RNA was quantified and the integrity was qualified (Agilent 2100
Bioanalyser, Agilent Technologies). Samples with insufficient RNA levels (RIN <8) were
excluded.
Total RNA (250ng) was converted to cDNA (Omniscript Reverse Transcriptase Qiagen).
Each reaction (20 µL), contained, 2µL of RT Buffer (1x), 2 µL of dNTPs (5mM), 2 µL of
oligo (dT) primer (0.4 ug/ul), 1 µL of RNase inhibitor (10U/ µL) (Invitrogen) and 1 µL of
omniscript reverse transcriptase (4U/ µL). Incubation was 37 °C for 1 hour; then 5 mins at 95
°C and included a no template control (NTC). Quantitative RT-PCR assays assessed the
number of mRNA transcripts (level of expression) for six genes, MLANA, ABCB5, TGFβ2,
PAX3d, MCAM and GAPDH. Each 15 µL reaction contained 1µL of cDNA template, 1x
SYBR GreenER qPCR SuperMix (Invitrogen) and 200nM of primer (Supplementary Table
1). Using an iCycler iQ5 Real-Time Thermocycler (BIO-RAD) incubation was as per the
manufacturer’s instructions.

To prevent contamination all PCR reactions contained Uracil-N-glycosylase to prevent
reamplification of carryover PCR products 39 and different steps were performed in separate
UV treatable areas. Tm determination and gel electrophoresis confirmed the expected size
and identity of PCR products.
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GAPDH, our internal reference for RT efficiency, is not up regulated in melanoma tissues or
cultured cells relative to normal samples 40; samples with insufficient levels were excluded.
Every assay included a standard curve, negative controls (NTC and reverse transcription
control), positive control (A2058 cell line) and cDNA from a single healthy control.
Standard Curve
A standard curve to quantify mRNA copy number, was constructed using larger PCR
products that included the target sequence used in qRT-PCR assays. For each standard, an
end point PCR primer set was designed (Supplementary Table 2). A2058 cDNA, synthesized
from 250ng of RNA, was used as a template. Using a Taq DNA polymerase kit (Qiagen),
each 20µL reaction consisted of 1x Coral Load buffer, 0.2mM of each dNTP, 2.5U of Taq
DNA polymerase, 1µL cDNA and 200nM of primer. Incubation involved: 94°C for 5
minutes, then 45 cycles of 94°C for 30 seconds, then 55°C for 30 seconds and 72°C for 1
minute. PCR products were purified after agarose gel electrophoresis using the freezesqueeze method 41. Resulting stock template solutions were quantified by spectrophotometric
analysis (Nanodrop, Thermo Scientific) and diluted into eight tenfold serial dilutions (101 108 copies/µL) from which a standard curve for each target was generated on the iCycler iQ5
Real-Time Thermocycler. Amplification efficiency of our target genes were between 96.4
and 100%. Samples were analysed in duplicate with averaged cT values used for relative
quantification. Relative mRNA copies for each transcript were calculated by dividing
absolute mRNA copies of the target by that of GAPDH.
Statistical Analysis
Pearson chi-square test and Fishers exact test were used to examine statistical significance of
marker expression between patient groups and controls. The Cochrane-Armitage trend test
8
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examined correlation between clinical stage, Clark level and/or expression level. Positive and
negative predictive values were calculated to examine the sensitivity of our test.
The relationship between level of marker expression and stage or presence of disease, was
investigated by Mann-Whitney U test and Kruskal-Wallis H test. Generalised linear
modelling was used to examine marker consistency. SPSS was used for analysis and
differences of p<0.05 were considered statistically significant.
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Results
Multimarker RT-PCR analysis was used to estimate the phenotype and quantity of circulating
cells in patient blood. Marker positivity and level of expression were analysed for correlation
with disease presence, stage, recurrence and treatment outcome.
Marker Expression in Patient Blood Relative to Controls:
Melanoma patients (92%, n=212) were significantly more likely to express a melanoma cell
marker in blood than were controls (59%, n=89) (p= 0.000, Odds ratio = 4.206, 95% CI
2.305-7.676). The number of markers expressed by participants was important, with 83%
(n=126) of healthy controls expressing either no marker or just one marker, in contrast to
melanoma patients, who were highly likely to express two or more markers (72%,
n=165)(p=0.012)(Table 1). The positive and negative predictive value of expressing a
marker, was 70% and 78% respectively. Expression of two or more melanoma markers
improved the positive predictive value to 86%, with a negative predictive value of 66%.
To identify the most informative markers, we analysed expression incidence of each marker
in patients. MLANA, ABCB5, MCAM, PAX3d, and TGFβ2 were detected in 30% (n=68),
40% (n=90), 47% (n=108), 40% (n=91), and 66% (n=152) of melanoma patients,
respectively.
Marker Expression in Patients Relative to Clinical Stage:
To assess marker utility, we analysed marker expression relative to clinical stage. MLANA
and ABCB5 were significantly more likely to be expressed in late stage patients (Stages IIIIV) (42% and 51%) than in early stage patients (0-II) (23% and 33%) (p=0.003 and p=0.006).
No other markers appeared to be stage related (Table 2).
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Clinical factors including primary location, Clark level, Breslow thickness and ulceration did
not correlate with marker expression (Table 3).
Pearson chi-square test was used to analyse whether the incidence of marker expression in
patient blood samples taken within one month of clinical diagnosis differ from samples taken
at times greater than one month following diagnosis. For most markers, expression did not
differ between samples taken at times less than and greater than one month following
diagnosis. TGFβ2 however, was expressed slightly more frequently in samples obtained
more than a month following diagnosis (47%, n=187) relative to samples collected within in
the first month following diagnosis (32%, n=50) (p=0.001). Samples taken at times greater
than one month after diagnosis were as likely to express a marker (79%, n=311), than
samples taken within the first month following diagnosis (71%, n=110).
Marker Expression Correlates to Disease Recurrence:
To investigate the prognostic value of our markers, the relationship between marker
expression and disease recurrence was analysed. Seventy three patients (32%) experienced
recurrence during our study and in these patients, both MLANA and ABCB5 were expressed
significantly more frequently (45%, n=33 and 49%, n=36) than in patients without recurrence
(23%, n=35, 34%, n=54) (p=0.001 and p=0.031) (Table 4). Patients with recurrence
expressed 5 markers more commonly (8%, n=6) than patients who experienced no recurrence
during our study (1%, n=2) (p=0.013). Patients with recurrence during our study were more
likely to express both ABCB5 and MLANA (26%, n=19) than patients without recurrence
during the study period (10%, n=15) (p=0.002). Co-expression of MLANA and ABCB5
produced a positive predictive value of 56% and a negative predictive value of 72%.
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When divided into stages, 48% of stage III-IV patients with recurrence (n=29) expressed
MLANA compared to only 19% of stage III-IV patients without recurrence (n=3) (p=0.033).
There was no correlation between MLANA expression and recurrence in early stage (0-II)
patients. Analysing the presence and level of markers relative to time since diagnosis in
patients who developed recurrence during our study, revealed markers were present in patient
blood at all stages, many years after diagnosis or surgical removal of the primary tumour,
even when there were no clinical signs of disease (Table 4).
Marker Expression in relation to Tumour Burden:
To examine if marker expression correlated with tumour burden, stage III-IV patients were
divided into those with one metastasis (n=16) (mean of tumour diameter: 19.8mm±13.2mm
(mean±SD)) or multiple metastases (mean of sum of tumour diameter: 76.5mm±36.06mm) at
the time of sampling (n=16). Only MCAM expression was significantly related to tumour
burden, with the level of expression greater among stage III-IV patients with multiple
metastases (1.23±1.66, n=4) than in those with only a single metastasis (0.67±0.49
(mean±SD), n=8,) (p=0.027).
Among stage III-IV patients, the surgical removal of a clinically measureable metastatic
tumour also influenced marker expression. MLANA and Pax3d were expressed less
frequently in patients following the surgical removal of a clinically measureable metastatic
tumour (18%, n=29; 19%, n=30), compared to patients with an existing tumour burden (48%,
n=16; 42%, n=14) (p=0.000 & p=0.003, respectively). A significant reduction in the level of
ABCB5 expression was observed in stage III-IV samples corresponding to the removal of a
clinically measureable metastasis (0.19±0.79), compared to samples with an existing tumour
burden (0.22±0.42)(p=0.011).
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Marker Expression in Relation to Clinical Treatment:
To analyse the effect of non-surgical treatment on circulating tumour cell phenotypes, marker
expression was investigated in 34 patients (15%) who received non-surgical treatment.
Treatments included: radiotherapy (n=29), interferon alfa 2b (n=5), limb infusion (n=1),
vaccine (n=4), chemotherapy (n=9) and radio frequency ablation (RFA) (n=1).
Three patients were sampled both before and after their non-surgical treatment, whereas the
majority of non-surgically treated patients were sampled during or following treatment. The
condition of two patients deteriorated post treatment, while the third remained stable (Figure
1). Patient 1 was sampled at diagnosis of a stage III melanoma, two months prior to
radiotherapy treatment of the left inguinal node, and expressed only ABCB5. Seventeen
months later, with their left axilla node identified as positive, the patient gained MLANA and
MCAM expression and the level of ABCB5 expression was maintained. No markers were
detected in patient 2, three months prior to RFA treatment for a lung metastasis. Sampled
three months after treatment, MLANA, ABCB5 and Pax3d were detected; the patient died
three months later. Patient 3 had positive lymph nodes and expressed no markers the day
before interferon alfa 2b treatment. Serial blood collections were then made at six, twelve,
twenty-one, and twenty-six months post treatment. TGFβ2 was detected at six, and twelve
months and TGFβ2, MCAM and ABCB5 were detected by twenty-six months with a 5 fold
decrease in MCAM between the last two serial samples.
The majority of the non-surgically treated stage IV samples were collected after non-surgical
treatment (n=26). To examine whether the phenotype of circulating melanoma cells reflects
the effectiveness of treatment, samples were divided into those from patients who had a
negative treatment outcome (n=40) (progression and/or death) and those with a positive
outcome (n=22) (disease remained stable or tumour size reduced). The expression of MCAM
13
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was significantly more common in patients with a negative treatment outcome with 43%
expressing MCAM (n=17), while only 9% of samples from patients with a positive outcome,
expressed this marker (n=2) (p=0.006)(Table 5). The positive predictive value for MCAM
expression as a marker of poor clinical outcome in patients with stage IV melanoma is
89.5%, while the negative predictive value is 46.5%.

Marker Consistency and Serial Blood Collection
21.7% of all acquired blood samples had a technical repeat (second PAXgene Blood RNA
tube) taken on the same day. Expression in these samples was highly consistent, with 70% of
duplicate samples having identical marker expression (n=273).
Generalised linear modelling was employed to examine serially collected samples (n=140),
acquired for each patient at intervals of six months over a period of two years. For the
majority of our markers, time was not a significant variable, with marker expression
remaining consistent, regardless of sampling time and regardless of stage (Supplementary
Table 3). For ABCB5 however, expression incidence significantly reduced over time (WaldChi = 16.209, p=0.000) in stage IV patients (Odds ratio: 0.2518, p=0.000, 95% CI 0.131,
0.483), which may represent the effect of non-surgical treatment on ABCB5 expression in
stage IV patients.
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Discussion:
This study showed that a multi marker qRT-PCR test for melanoma circulating cells
correlated with melanoma diagnosis. Very few melanoma patients expressed no markers at
all, only 7%. A significant number of healthy controls, however also expressed one marker.
Therefore, patients and controls are best differentiated by the number of markers expressed
i.e. by a multi marker test.
Multiple markers were detected at all disease stages, even in early stage patients, however the
incidence was lower in these patients than in later stage patients. In contrast to previous
papers 18,42, the levels and number of markers were not stage related, possibly related to the
use of ABCB5 and TGFβ2, both previously unused markers of circulating tumour cells.
TGFβ2 was the most common marker in controls, so cannot be recommended as a single
marker for patient analysis.
By contrast, ABCB5, described by Frank and colleagues in 2003 was a highly informative
marker 23,24,31,36. ABCB5 reportedly represents a subset of melanoma cells with a stem cell
phenotype and is thought here to represent a subset of heterogeneous circulating melanoma
cells present at all disease stages. In this study it was identified as a potential predictor of
active recurrence/progression events with its expression in blood correlating with disease
recurrence and progression in patients, a finding that warrants further testing of this marker.
This marker was detected amongst patients regardless of whether or not they were considered
clinically disease free, indicating that these stem - like circulating cells remain for long
periods in the blood. A role for ABCB5 cells in disease spread has been demonstrated in
mouse -to-mouse transplantation experiments, where circulating ABCB5 expressing tumour
cells were shown to be capable of initiating metastatic disease after transplantation into donor
mice 23.
15
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Besides ABCB5, MLANA expression was also a potential predictor of recurrence events in
our patient cohort. Since ABCB5 positive cells do not co-express MLANA24, circulating cells
must therefore include both stem and non-stem cell phenotypes during recurrence. This may
reflect a change in stem cell to a non-stem cell phenotype during formation of the metastatic
tumour43. Previous studies described MLANA expression as correlating with disease stage25,
and in this study both MLANA and ABCB5 expression correlated with disease stage, with
expression more common in advanced (stage III-IV) than in early stage (stage 0-II) patients.
In fact, removal of a clinically measurable metastasis significantly reduced the expression of
Pax3d, ABCB5 and MLANA in stage III-IV patients, signifying the importance of metastases
in maintaining the hematogenous spread of tumour cells 44,7.
Utilising these markers, circulating tumour cells were detected at all disease stages long after
surgical treatment, even when a patient was considered clinically disease free. Thus, as found
in previous studies of circulating tumour cells 42,45, the mere presence of circulating tumour
cells does not always correlate with disease stage or metastatic recurrence, and additional
markers are required to stratify those early stage patients likely to have disease progression.
In our study MCAM expression correlated with increased tumour burden, a result consistent
with recent in vivo studies with nude mice that revealed a significant correlation between
MCAM expression and the formation of metastases 46. MCAM was also the most suitable
marker for monitoring response to therapy and indicates, presumably, ineffective eradication
of circulating melanoma cells, evidenced here by an increase in the incidence of MCAM
expression in patients with a negative treatment outcome. MCAM expression could therefore
be used to monitor treatment resistance or risk of relapse. Given MCAM expression is
thought to play a role in cell-cell and cell-matrix interactions during formation of metastases,
the expression of MCAM in circulating cells may aid in the spread of malignant melanoma
16
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cells throughout the body 7,44. A previous study found MCAM to be a predictor of poor
patient survival and disease prognosis 43. Overall, 68% of non-surgically treated patients had
a negative treatment outcome, highlighting the poor response rate of patients to non-surgical
treatments and reflected here by 64% of these patients expressing MCAM. Essentially,
MCAM expression may aid in identifying a subset of patients with metastatic disease who
respond poorly to conventional systemic treatments and may benefit from an alternative
treatment regime.
Some p-values were achieved by considering several different predictors. However,
corrections were not made for multiple comparisons because the markers were considered to
be independent. Moreover, even when we applied Bonferroni corrections to secondary
hypotheses for 5 comparisons, the majority of hypotheses remained significant (p<0.01); for
example, comparisons between early versus late disease stage (MLANA p = 0.003 and
ABCB5 p=.006), disease recurrence (MLANA p=0.001) and negative treatment outcome
(MCAM p=0.006) remain significant. Only the correlation of MCAM expression and tumour
burden (MCAM p = 0.027), and ABCB5 expression in relation to recurrence (ABCB5
p=0.031) and the surgical removal of a clinically measurable lesion (ABCB5 p=0.011) are no
longer significant. Despite this, MCAM and ABCB5 remain valuable markers of clinical
outcome and disease recurrence, especially ABCB5 expression in combination with
MLANA.
It is clear that circulating tumour cells are detectable at all stages of disease and the specific
detection of ABCB5, MLANA and MCAM expressing tumour cells in blood may be of
prognostic value. Importantly, we demonstrated that a qRT-PCR multi-marker blood test
provides a suitable method from which to develop further a reliable test for monitoring
disease status without the need for specific isolation of circulating tumour cells.
17
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Tables
Table 1 – Number of markers detected in the peripheral blood of patients and healthy
controls.
Number of
markers

0

1

2

3

4

5

n

8 (18)

20 (47)

34 (79)

23 (54)

10 (24)

3 (8)

230

41 (63)

41 (63)

11 (17)

4 (6)

2 (3)

0

152

% (n)
CMM Patients
Healthy controls
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Table 2 - qRT-PCR Marker detection in the peripheral blood of healthy controls and in
melanoma patients categorised by AJCC stage.

AJCC staged melanoma patients % (n)
Markers

0

I

II

III

IV

Healthy Controls

MLANA

26 (10)

25 (19)

18 (7)

40 (12)

43 (20)

13 (19)

45 (17)

27 (21)

33 (13)

50 (15)

52 (24)

22 (33)

Pax3d

47 (18)

30 (23)

36 (14)

50 (15)

46 (21)

14 (21)

MCAM

42 (16)

49 (38)

46 (18)

53 (16)

43 (20)

14 (21)

TGFβ2

63 (24)

64 (49)

74 (29)

77 (23)

59 (27)

22 (33)

N

38

77

39

30

46

152

ABCB5

23
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Table 3 - Melanoma patient characteristics
Prognostic factor
Gender

AJCC Stage

Primary Site

Breslow thickness (primary) mm

Clark level

Ulceration

Number of patients
Males

81

Females

149

0

38

I

77

II

39

III

30

IV

46

Face

36

Torso

78

Arms

31

Legs

37

Scalp

14

No primary lesion or unknown

34

<1mm

103

1-4mm

82

>4mm

20

Unknown

25

I

43

II

30

III

20

IV

81

V

15

Unknown

41

No

178

Yes

34

Unknown

18

24
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Table 4 - qRT-PCR Marker detection in the peripheral blood of melanoma patients
categorised by recurrence and time since diagnosis.

Patients with recurrence during study period
% (n)

Time since diagnosis in relation to sampling in
patients with recurrence % (n)

Markers

recurrence

no recurrence

< 1 month

< 1 year

< 5 years

> 5 years

MLANA

*45 (33)

23 (35)

33 (2)

18 (7)

26 (32)

22 (18)

*49 (36)

34 (54)

0

18 (7)

22 (27)

32 (26)

Pax3d

41 (30)

39 (61)

33 (2)

21 (8)

22 (27)

15 (12)

MCAM

49 (36)

46 (72)

0

21 (8)

21 (26)

25 (25)

TGFβ2

63 (46)

68 (106)

50 (3)

29 (11)

34 (42)

34 (34)

157

6

38

124

81

ABCB5

73
N
P-value* - Pearson chi-square test, p<0.01
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Table 5 – MCAM expression in the peripheral blood of stage IV melanoma patients in
relation to clinical outcome.
MCAM expression % (n)
Clinical Outcome
Negative (disease progression and/or death)
Positive (disease remained stable or tumour size reduced)

+

-

N

43 (17)

58 (23)

40

9 (2)

91 (20)

22

26

